NCT05922709View on ClinicalTrials.gov

A Clinical Trial of CS12192 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

July 20, 2023

Primary Completion Date

February 1, 2024

Study Completion Date

February 1, 2024

Conditions
Healthy
Interventions
DRUG

CS12192 capsule

Participants receive CS12192 orally single or multiple doses

DRUG

Placebo capsule

Participants receive placebo matching CS12192 orally single or multiple doses

Trial Locations (1)

200032

Zhongshan Hospital Affiliated to Fudan University, Shanghai

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY